When Improved Iron Nutrition Benefits the Pathogen and Adversely Affects the Host: A Review of Iron Metabolism in HIV-1 Infection

Authors

  • Uduak A. Udofia Department of Medical Biochemistry, Faculty of Basic Medical Sciences, University of Uyo, Akwa-ibom, Nigeria Author https://orcid.org/0009-0007-4919-7755

Keywords:

HIV-1; Iron metabolism; Hepcidin; Nutritional immunity; Anemia of inflammation; Iron chelation

Abstract

Iron is an essential micronutrient for both host immune function and pathogen proliferation. In the context of Human Immunodeficiency Virus type 1 (HIV-1) infection, the management of iron status presents a complex clinical paradox. While iron deficiency contributes to anemia and impaired erythropoietic and immune function, excessive iron availability or inappropriate iron supplementation may exacerbate oxidative stress and support iron-dependent cellular processes that can favor viral persistence and replication. HIV-1 critically depends on host cellular machinery, including iron-dependent enzymes and pathways such as ribonucleotide reductase, deoxyhypusine hydroxylase, and redox-sensitive Nuclear Factor kappa B (NF-κB) signaling. In parallel, the host deploys nutritional immunity through the hepcidin-ferroportin axis to restrict circulating iron and promote its sequestration within macrophages. Emerging evidence also implicates iron-sulfur cluster-dependent host proteins and ferroptotic pathways in HIV-associated cellular pathology, although their broader contribution to HIV-1 pathogenesis remains incompletely defined. This review examines HIV-1 biology, viral replication, host immune interactions, and iron metabolism, with emphasis on the mechanisms linking iron dysregulation to anemia, oxidative stress, macrophage dysfunction, and viral persistence. Furthermore, we evaluate the clinical implications of iron supplementation, the importance of distinguishing true iron deficiency from anemia of inflammation, potential interactions between iron-containing supplements and integrase strand transfer inhibitors, and the emerging therapeutic potential and limitations of iron chelators as host-directed antiviral agents.

 

Downloads

Download data is not yet available.

References

Abonyo, C., Kiboi, N., & Shaviya, N. (2025). Tracking biomarkers of iron dysregulation across HIV treatment spectrum: Insights from erythroferrone, hepcidin and hephaestin levels in Western Kenya. Science Mundi, 5(2), 85–94.

Andrus, L., Szabo, P., Grady, R. W., Hanauske, A. R., Huima-Byron, T., Slowinska, B., Zagulska, S., & Hanauske-Abel, H. M. (1998). Antiretroviral effects of deoxyhypusyl hydroxylase inhibitors: A hypusine-dependent host cell mechanism for replication of human immunodeficiency virus type 1 (HIV-1). Biochemical Pharmacology, 55(11), 1807–1818.

Arora, P., Hindman, J. T., West, S., Ling, J., Palaparthy, R., & Marathe, D. D. (2026). The effect of antacid and mineral supplements on bictegravir pharmacokinetics: Results from a phase 1, open-label, drug–drug interaction study. Antimicrobial Agents and Chemotherapy, 70(1), e00781-25.

Boelaert, J. R., Gordeuk, V. R., Belpaire, F. M., Clement, M. G., & Kusnecov, A. W. (1996). Altered iron metabolism in HIV infection: Mechanisms, possible consequences, and proposals for management. Infectious Agents and Disease, 5(1), 36–46.

Brenchley, J. M., Price, D. A., Schacker, T. W., Asher, T. E., Silvestri, G., Rao, S., Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D., Blazar, B. R., Rodriguez, B., Teixeira-Johnson, L., Landay, A., Martin, J. N., Hecht, F. M., Picker, L. J., Lederman, M. M., Deeks, S. G., & Douek, D. C. (2006). Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine, 12, 1365–1371.

Bresgen, N., & Eckl, P. M. (2015). Oxidative stress and the homeostatic control of iron. Biomolecules, 5(4), 2247–2273.

Dooher, J. E., Schneider, B. L., Reed, J. C., & Lingappa, J. R. (2007). Host ABCE1 is at plasma membrane HIV assembly sites and its dissociation from Gag is linked to subsequent events of virus production. Traffic, 8(3), 195–211.

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., Morrison, B., III, & Stockwell, B. R. (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 149(5), 1060–1072.

Drakesmith, H., & Prentice, A. M. (2012). Viral infection and iron metabolism. Nature Reviews in Microbiology, 10(12), 856–868.

Engelman, A., & Cherepanov, P. (2012). The structural biology of HIV-1: Mechanistic and therapeutic insights. Nature Reviews in Microbiology, 10(4), 279–290.

Freed, E. O. (2001). HIV-1 replication. Somatic Cell and Molecular Genetics, 26(1), 13–33.

Galaris, D., & Pantopoulos, K. (2008). Oxidative stress and iron homeostasis: Mechanisms and health implications. Critical Reviews in Clinical Laboratory Sciences, 45(1), 1–23.

Ganz, T. (2003). Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood, 102(3), 783–788.

Georgiou, N. A., van der Bruggen, T., Oudshoorn, M., Nottet, H. S. L. M., Marx, J. J. M., & van Asbeck, B. S. (2000). Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. The Journal of Infectious Diseases, 181(2), 484–490.

Gizzi, A. S., Grove, T. L., Arnold, J. J., Jose, J., Jangra, R. K., Garforth, S. J., Du, Q., Cahill, S. M., Dulyaninova, N. G., Love, J. D., Chandran, K., Bresnick, A. R., Cameron, C. E., & Almo, S. C. (2018). A naturally occurring antiviral ribonucleotide encoded by the human genome. Nature, 558, 610–614.

Goldschmidt, V. (2006). Mg2+ dependency of HIV-1 reverse transcription, inhibition by nucleoside analogues and resistance. Nucleic Acids Research, 34, 42–52.

Gordeuk, V. R., Delanghe, J. R., Langlois, M. R., & Boelaert, J. R. (2001). Iron status and the outcome of HIV infection: An overview. Journal of Clinical Virology, 20(3), 111–115.

Hoque, M., Hanauske-Abel, H. M., Palumbo, P., Saxena, D., D'Alliessi Gandolfi, D., Park, M. H., Pe'ery, T., & Mathews, M. B. (2009). Inhibition of HIV-1 gene expression by ciclopirox and deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology, 6, 90.

Kannan, M., Sil, S., Oladapo, A., Thangaraj, A., Periyasamy, P., & Buch, S. (2023). HIV-1 Tat-mediated microglial ferroptosis involves the miR-204–ACSL4 signaling axis. Redox Biology, 62, 102689.

Kell, D. B. (2009). Iron behaving badly: Inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Medical Genomics, 2, Article 2.

Klein, K. C., Reed, J. C., Tanaka, M., Nguyen, V. T., Giri, S., & Lingappa, J. R. (2011). HIV Gag-leucine zipper chimeras form ABCE1-containing intermediates and RNase-resistant immature capsids similar to those formed by wild-type HIV-1 Gag. Journal of Virology, 85, 7419–7435.

Krishna, R., East, L., Larson, P., Valiathan, C., Butterfield, K., Teng, Y., & Hernandez-Illas, M. (2016). Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. Journal of Pharmacy and Pharmacology, 68(11), 1359–1365.

Kumar, N., Sharma, S., Kumar, R., Tripathi, B. N., Barua, S., Ly, H., & Rouse, B. T. (2020). Host-directed antiviral therapy. Clinical Microbiology Reviews, 33(3), e00168-19.

Lill, R. (2020). From the discovery to molecular understanding of cellular iron-sulfur protein biogenesis. Biological Chemistry, 401, 855–876.

Lounis, N., Truffot-Pernot, C., Grosset, J., Gordeuk, V. R., & Boelaert, J. R. (2001). Iron and Mycobacterium tuberculosis infection. Journal of Clinical Investigation, 107(5), 593–598.

Maio, N., & Rouault, T. A. (2020). Outlining the complex pathway of mammalian Fe-S cluster biogenesis. Trends in Biochemical Sciences, 45, 411–426.

Minchella, P. A., Armitage, A. E., Darboe, B., Jallow, M. W., Drakesmith, H., Jaye, A., Prentice, A. M., & McDermid, J. M. (2015). Elevated hepcidin is part of a complex relation that links mortality with iron homeostasis and anemia in men and women with HIV infection. The Journal of Nutrition, 145(6), 1194–1201.

Nekhai, S., Kumari, N., & Sharma, S. (2013). Role of iron and heme in HIV-1 infection and antiretroviral therapy. Viruses, 5(11), 2848–2882.

Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 306(5704), 2090–2093.

Nordlund, P., & Reichard, P. (2006). Ribonucleotide reductases. Annual Review of Biochemistry, 75, 681–706.

Obeagu, E. I., Obeagu, G. U., Ukibe, N. R., & Oyebadejo, S. A. (2024). Anemia, iron, and HIV: Decoding the interconnected pathways: A review. Medicine, 103(2), e36937.

Park, M. H. (2006). The essential role of hypusine in eukaryotic translation initiation factor 5A (eIF5A) in cellular proliferation and development. Amino Acids, 30(2), 163–171.

Punnonen, K., Irjala, K., & Rajamäki, A. (1997). Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood, 89(3), 1052–1057.

Sappey, C., Boelaert, J. R., Legrand-Poels, S., Forceille, C., Favier, A., & Piette, J. (1995). Iron chelation decreases NF-kappa B and HIV type 1 activation due to oxidative stress. AIDS Research and Human Retroviruses, 11(9), 1049–1061.

Saxena, D., Spino, M., Tricta, F., Connelly, J., Cracchiolo, B. M., Hanauske, A.-R., D’Alliessi Gandolfi, D., Mathews, M. B., Karn, J., Holland, B., Park, M. H., Pe’ery, T., Palumbo, P. E., & Hanauske-Abel, H. M. (2016). Drug-based lead discovery: The novel ablative antiretroviral profile of deferiprone in HIV-1-infected cells and in HIV-infected treatment-naive subjects of a double-blind, placebo-controlled, randomized exploratory trial. PLOS ONE, 11, e0154842.

Scarsi, K. K., Havens, J. P., Podany, A. T., Avedissian, S. N., & Fletcher, C. V. (2020). HIV-1 integrase inhibitors: A comparative review of efficacy and safety. Drugs, 80(16), 1649–1676.

Schreck, R., Rieber, P., & Baeuerle, P. A. (1991). Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. The EMBO Journal, 10(8), 2247–2258.

Stockwell, B. R. (2022). Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell, 185(14), 2401–2421.

Thierry, E., Deprez, E., & Delelis, O. (2017). Different pathways leading to integrase inhibitors resistance. Frontiers in Microbiology, 7, 2165.

U.S. Food and Drug Administration (2025). Ferriprox (deferiprone): Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021825s012lbl.pdf

U.S. National Library of Medicine (2026). Deferoxamine mesylate injection: Drug information and prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9ab6b1c-98d0-4373-0e9b-b10cb4a67543

Upadhyay, A. S., Stehling, O., Panayiotou, C., Rösser, R., Lill, R., & Överby, A. K. (2017). Cellular requirements for iron–sulfur cluster insertion into the antiviral radical SAM protein viperin. Journal of Biological Chemistry, 292, 13879–13889.

ViiV Healthcare. (2024). Tivicay (dolutegravir) prescribing information. U.S. Food and Drug Administration.

Volberding, P. A., Levine, A. M., Dieterich, D., Mildvan, D., Mitsuyasu, R., & Saag, M. (2004). Anemia in HIV infection: Clinical impact and evidence-based management strategies. Clinical Infectious Diseases, 38(10), 1454–1463.

Ward, R. J., Wilmet, S., Legssyer, R., & Crichton, R. R. (2002). The influence of iron homoeostasis on macrophage function. Biochemical Society Transactions, 30(4), 762–765.

Weinberg, E. D. (1974). Iron and susceptibility to infectious disease. Science, 184(4140), 952–956.

Weiss, G., & Goodnough, L. T. (2005). Anemia of chronic disease. New England Journal of Medicine, 352(10), 1011–1023.

Weiss, G., Ganz, T., & Goodnough, L. T. (2019). Anemia of inflammation. Blood, 133(1), 40–50.

Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., Brown, L. M., Girotti, A. W., Cornish, V. W., Schreiber, S. L., & Stockwell, B. R. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell, 156(1–2), 317–331.

Zhang, R., Bloch, N., Nguyen, L. A., Kim, B., & Landau, N. R. (2014). SAMHD1 restricts HIV-1 replication and regulates interferon production in mouse myeloid cells. PLoS ONE, 9, e89558.

Zhao, A. V., Crutchley, R. D., Guduru, R. C., Ton, K., Lam, T., & Min, A. C. (2022). A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Retrovirology, 19, 22.

Additional Files

Published

2026-09-11

Data Availability Statement

Data availability is not applicable to this review article, as no new datasets were generated or analyzed.

Issue

Section

Research Articles

Categories

How to Cite

When Improved Iron Nutrition Benefits the Pathogen and Adversely Affects the Host: A Review of Iron Metabolism in HIV-1 Infection. (2026). Nigerian Journal of Biochemistry and Molecular Biology, 40(3), 348-356. https://www.nsbmb.org.ng/journals/index.php/njbmb/article/view/699

Similar Articles

81-90 of 124

You may also start an advanced similarity search for this article.